Aarti Pharmalabs Limited (APL) is a premier India-based small-molecule CDMO providing end-to-end Contract Development and Manufacturing (CMC) services for critical drug substances. Specializing in New Chemical Entities (NCEs), Highly Potent APIs (HPAPIs), Regulatory Starting Materials (RSMs), and advanced intermediates, APL supports global pharmaceutical and biotechnology innovators across the complete development lifecycle—transitioning programs seamlessly from initial laboratory benchwork and pilot scale through clinical trials, launch, and full-scale commercial manufacturing.
Our operational model is defined by deep scientific excellence, speed, flexibility, and close collaboration. Operating as a direct extension of our clients’ internal laboratories and teams, our dedicated scientific and project units work side-by-side with partners to solve complex chemistry challenges, accelerate development timelines, and ensure efficient, dependable scale-up. This integrated approach ensures consistent quality, transparent communication, and reliable execution at every clinical and commercial milestone.
Driven by a shared mission to deliver innovative medicines to patients faster, APL is committed to being the preferred CDMO partner for innovators worldwide. We recognize the profound responsibility of stewarding our clients’ pipeline assets, and we continuously earn that trust through rigorous technical standards, rapid responsiveness, strict quality systems, and an enduring culture of shared success.
